HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bem, R. Articles by Jude, E. B. Search for Related Content PubMed PubMed Citation Articles by Bem, R. Articles by Jude, E. B. Social Bookmarking                What's this?

Intranasal Calcitonin in the Treatment of Acute Charcot Neuroosteoarthropathy

A randomized controlled trial

¹ Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
² Diabetes Centre, Tameside General Hospital, Ashton-Under-Lyne, Lancashire, U.K.

Address correspondence and reprint requests to Robert Bem, MD, Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 4, 14021, Czech Republic.E-mail: bemrob@yahoo.co.uk

Abbreviations: 1CTP, COOH-terminal telopeptide region of type 1 collagen • BALP, bone-specific alkaline phosphatase • CNO, Charcot neuroosteoarthropathy

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
Charcot neuroosteoarthropathy (CNO) can lead to disruption of the bone architecture of the foot (1). Increased osteoclastic activity is believed to be responsible for the bone destruction in CNO (2). Previous studies showed COOH-terminal telopeptide region of type 1 collagen (1CTP) and bone-specific alkaline phosphatase (BALP) as useful markers of bone turnover in patients with CNO (3–5).

Presently, only bisphosphonates have been demonstrated to have some benefit in patients with CNO (6). However, bisphosphonates may have potential disadvantages in that they decrease bone remodeling and are contraindicated in patients with renal insufficiency (7).

Our previous study (8) showed positive effects of calcitonin on bone resorption in patients with acute CNO. In this study, we set out to assess the effect of calcitonin on bone metabolism and disease activity during a 6-month treatment with intranasal calcitonin in acute CNO.

	REASERCH DESIGN AND METHODS

 
Thirty-two consecutive patients with acute CNO were entered into the study. Subjects were recruited from our diabetic foot clinic during a 17-month period and were followed up for 6 months. The study was approved by the local ethics committee, and all participants gave written informed consent.

Acute CNO was defined by clinical signs: warm, swollen foot and skin temperatures 2°C at the site of maximum deformity of the affected foot compared with a similar site on the contralateral foot (infrared thermometer) and confirmed by plain X-ray and three-phase technetium bone scan (9). The presence of diabetic neuropathy was . . . [Full Text of this Article]

	RESULTS

 

	CONCLUSIONS

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. A. Ayoub Ankle fractures in diabetic neuropathic arthropathy: CAN TIBIOTALAR ARTHRODESIS SALVAGE THE LIMB? J Bone Joint Surg Br, July 1, 2008; 90-B(7): 906 - 914. [Abstract] [Full Text] [PDF]